Impact of Quality Improvement Interventions on Biopsy-to-Treatment Time in Breast Cancer: Results from the PROMPT Quality Collaborative of the National Accreditation Program for Breast Centers
- PMID: 40783671
- DOI: 10.1245/s10434-025-17935-0
Impact of Quality Improvement Interventions on Biopsy-to-Treatment Time in Breast Cancer: Results from the PROMPT Quality Collaborative of the National Accreditation Program for Breast Centers
Abstract
Background: To address the interval between biopsy and first treatment, the National Accreditation Program for Breast Centers (NAPBC) launched Patient-Reported Observations for Medical Procedure Timeliness (PROMPT), a quality collaborative.
Methods: Participating PROMPT sites submitted data on the number of days from biopsy to first treatment (either surgery or neoadjuvant treatment (NAC)) before and after individual site-specific quality improvement (QI) projects using the American College of Surgeons Quality Framework. The study examined interventions of sites that reported successful projects and barriers for both successful and unsuccessful sites.
Results: Of 104 PROMPT sites, 62 (59.6 %) examined the time from biopsy to surgery, and 42 (40.4 %) analyzed the time from biopsy to NAC. Overall, 56 (53.8 %) sites decreased their interval from biopsy to treatment, from 50.3 to 38.8 days for biopsy to surgery and from 40.7 to 30.9 days for biopsy to NAC. No facility factors were associated with successfully decreasing this interval. The most common intervention for both intervals was enabling navigators to schedule appointments for surgeons and medical oncologists. Of 22 interventions for the interval from biopsy to surgery, the most common included hiring a breast surgeon and increasing operating room (OR) block time for surgeons. Of 17 interventions for the interval from biopsy to NAC, the most common were streamlining port-a-cath placements, ordering staging studies before seeing medical oncology, and offering concurrent medical oncology and surgery appointments.
Conclusions: Just more than half of the PROMPT sites improved their interval. Interventions to improve timely care include hiring staff and improving scheduling.
Keywords: Biopsy to treatment; Breast cancer; Neoadjuvant therapy; PROMPT collaborative; Patient navigation; Quality improvement; Surgical timeliness; Treatment delay.
© 2025. Society of Surgical Oncology.
Conflict of interest statement
Disclosure: Jill Dietz: is CMO of Cyduct diagnostics with options of honorarium travel expenses for Endomag and Lumicell.
Similar articles
-
Falls prevention interventions for community-dwelling older adults: systematic review and meta-analysis of benefits, harms, and patient values and preferences.Syst Rev. 2024 Nov 26;13(1):289. doi: 10.1186/s13643-024-02681-3. Syst Rev. 2024. PMID: 39593159 Free PMC article.
-
[Volume and health outcomes: evidence from systematic reviews and from evaluation of Italian hospital data].Epidemiol Prev. 2013 Mar-Jun;37(2-3 Suppl 2):1-100. Epidemiol Prev. 2013. PMID: 23851286 Italian.
-
Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.Clin Orthop Relat Res. 2024 Dec 1;482(12):2193-2208. doi: 10.1097/CORR.0000000000003185. Epub 2024 Jul 23. Clin Orthop Relat Res. 2024. PMID: 39051924
-
Interventions for treating painful nipples among breastfeeding women.Cochrane Database Syst Rev. 2014 Dec 15;2014(12):CD007366. doi: 10.1002/14651858.CD007366.pub2. Cochrane Database Syst Rev. 2014. PMID: 25506813 Free PMC article.
-
Prophylactic mastectomy for the prevention of breast cancer.Cochrane Database Syst Rev. 2004 Oct 18;(4):CD002748. doi: 10.1002/14651858.CD002748.pub2. Cochrane Database Syst Rev. 2004. Update in: Cochrane Database Syst Rev. 2010 Nov 10;(11):CD002748. doi: 10.1002/14651858.CD002748.pub3. PMID: 15495033 Updated.
References
-
- Pratt D, Burneikis T, Tu C, Grobmyer S. Time to completion of breast cancer treatment and survival. Ann Surg Oncol. 2021;28:8600–8. https://doi.org/10.1245/s10434-021-10116-9 . - DOI - PubMed
-
- Zhu S, Li S, Huang J, Fei X, Shen K, Chen X. Time interval between breast cancer diagnosis and surgery is associated with disease outcome. Sci Rep. 2023;13:12091. https://doi.org/10.1038/s41598-023-39259-3 . - DOI - PubMed - PMC
-
- Kou K, Aitken JF, Pyke C, Chambers S, Dunn J, Baade PD. Treatment intervals and survival for women diagnosed with early breast cancer in Queensland: the Breast Cancer Outcomes Study, a population-based cohort study. Med J Aust. 2023;219:409–16. https://doi.org/10.5694/mja2.52091 . - DOI - PubMed
-
- Thompson DM, Fefferman ML, Nicholson KM, et al. Time from screening to treatment at accredited breast centers in the United States. JCO Oncol Pract. 2025;21(6): 781-790. https://doi.org/10.1200/OP-24-00516 . - DOI - PubMed
-
- Dunn MR, Li D, Emerson MA, et al. A latent class assessment of healthcare access factors and disparities in breast cancer care timeliness. PLoS Med. 2024;21:e1004500. https://doi.org/10.1371/journal.pmed.1004500 . - DOI - PubMed - PMC
Grants and funding
LinkOut - more resources
Full Text Sources